Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
23 November 2020Website:
http://www.23andme.comNext earnings report:
07 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 61 min agoDividend
Analysts recommendations
Institutional Ownership
ME Latest News
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360™ development engine to enable target validation and precision medicine.
23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its therapeutics business and winding down its clinical trials; it expects these changes to save $35 million annually.
Genetic testing firm 23andMe announced plans to cut 40% of its workforce, or around 200 jobs, as part of a cost-saving effort aimed at stabilising the company. It will also halt work on its therapy development projects, exploring options to license or sell them.
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
Genetic testing firm 23andMe said on Monday it is reducing its overall headcount by over 200 employees or about 40% of the workforce, as part of a restructuring program.
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced a business restructuring to streamline operations and reduce costs.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress.
23andMe said it appointed three new independent directors to its board on Monday. All seven of 23andMe's previous directors resigned in September over its "strategic direction.
23andMe appointed three new independent directors to its board, the company said Tuesday. The announcement comes about a month after all seven of 23andMe's previous independent directors abruptly resigned.
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the “Board”), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In addition, Mr. Jensen has been appointed to serve as the Board's Lead Independent Director.
What type of business is 23andMe Holding Co?
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.
What sector is 23andMe Holding Co in?
23andMe Holding Co is in the Healthcare sector
What industry is 23andMe Holding Co in?
23andMe Holding Co is in the Diagnostics & Research industry
What country is 23andMe Holding Co from?
23andMe Holding Co is headquartered in United States
When did 23andMe Holding Co go public?
23andMe Holding Co initial public offering (IPO) was on 23 November 2020
What is 23andMe Holding Co website?
https://www.23andme.com
Is 23andMe Holding Co in the S&P 500?
No, 23andMe Holding Co is not included in the S&P 500 index
Is 23andMe Holding Co in the NASDAQ 100?
No, 23andMe Holding Co is not included in the NASDAQ 100 index
Is 23andMe Holding Co in the Dow Jones?
No, 23andMe Holding Co is not included in the Dow Jones index
When was 23andMe Holding Co the previous earnings report?
No data
When does 23andMe Holding Co earnings report?
The next expected earnings date for 23andMe Holding Co is 07 February 2025